

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-73 (Canceled)

Claim 74 (Currently amended): A ~~pharmaceutical~~ composition comprising a peptide having less than fifteen amino acids and a pharmaceutically acceptable carrier, wherein:

the peptide comprises an epitope consisting of ~~about~~ 8 to about 11 amino acids;
and

the epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.

Claim 75 (Canceled)

Claim 76 (Currently amended): A ~~pharmaceutical~~ composition comprising a peptide having less than fifteen amino acids and a pharmaceutically acceptable carrier, wherein:

the peptide comprises an epitope consisting of ~~about~~ 8 to about 11 amino acids;

the epitope is an HIV-1 epitope; and

the epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.

Claim 77 (Currently amended): A ~~pharmaceutical~~ composition consisting essentially of a peptide epitope having ~~about~~ 8 to about 11 amino acids and a pharmaceutically acceptable carrier, wherein the peptide epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the peptide epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.

Claim 78 (Canceled)

Claim 79 (Currently amended): A ~~pharmaceutical~~ composition consisting essentially of a peptide epitope having ~~about~~ 8 to about 11 amino acids and a pharmaceutically acceptable carrier, wherein:

the peptide epitope is an HIV-1 peptide epitope; and

the peptide epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the peptide epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.

Claim 80 (Currently amended): The ~~pharmaceutical~~ composition of any one of claims 74, 76, 77, or 79 ~~74-79~~, wherein the amino acid at position two from the amino terminal amino acid of the epitope is selected from the group consisting of L, M, V, and T and the C-terminal amino acid is K.

Claim 81 (Currently amended): The ~~pharmaceutical~~ composition of claim 80, wherein the amino acid at position two from the amino terminal amino acid of the epitope is T and the C-terminal amino acid is K.

Claim 82 (Currently amended): The ~~pharmaceutical~~ composition of claim 81, wherein the epitope consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 83 (Currently amended): A diagnostic reagent comprising a peptide having less than fifteen amino acids, wherein:

the peptide comprises an epitope consisting of ~~about~~ 8 to about 11 amino acids;
and

the epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.

Claim 84 (Currently amended): A diagnostic reagent comprising a peptide having less than fifteen amino acids, wherein:

the peptide comprises an epitope consisting of ~~about~~ 8 to about 11 amino acids;
the epitope is an HIV-1 epitope; and

the epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.

Claim 85 (Currently amended): A diagnostic reagent consisting essentially of a peptide epitope having ~~about~~ 8 to about 11 amino acids, wherein the peptide epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the peptide epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.


Claim 86 (Currently amended): A diagnostic reagent consisting essentially of a peptide epitope having ~~about~~ 8 to about 11 amino acids, wherein:

the peptide epitope is an HIV-1 peptide epitope; and

the peptide epitope comprises ~~corresponds to~~ an HLA-A3 motif having an amino acid at position two from the amino terminal amino acid of the peptide epitope selected from the group consisting of L, M, V, S, A, T, and F and having K as the C-terminal amino acid.

Claim 87-90 (Canceled)

Claim 91 (Previously amended): An isolated antigenic HLA-A3 binding peptide derived from a HIV-1 protein having the following formula:



wherein Xaa₂ is Leu, Met, Ile, Val, Ser, or Thr, and Xaa₁₀ is Lys or Arg, and said isolated peptide provides lysis by cytotoxic T cells specific for a complex of said HLA molecule and said decapeptide. (SEQ ID NO:104)

Claim 92 (Canceled)

Claim 93 (Previously amended): The isolated antigenic HLA-A3 binding peptide of claim 92 consisting of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 94 (Canceled)

Claim 95 (New): The diagnostic agent of claim 82, wherein the amino acid at position two from the amino terminal amino acid of the epitope is selected from the group consisting of L, M, V, and T and the C-terminal amino acid is K.

Claim 96 (New): The diagnostic agent of claim 95, wherein the amino acid at position two from the amino terminal amino acid of the epitope is T and the C-terminal amino acid is K.

Claim 97 (New): The diagnostic agent of claim 96, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 98 (New): The diagnostic agent of claim 83, wherein the amino acid at position two from the amino terminal amino acid of the epitope is selected from the group consisting of L, M, V, and T and the C-terminal amino acid is K.

Claim 99 (New): The diagnostic agent of claim 98, wherein the amino acid at position two from the amino terminal amino acid of the epitope is T and the C-terminal amino acid is K.

Claim 100 (New): The diagnostic agent of claim 99, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 101 (New): The diagnostic agent of claim 84, wherein the amino acid at position two from the amino terminal amino acid of the epitope is selected from the group consisting of L, M, V, and T and the C-terminal amino acid is K.

Claim 102 (New): The diagnostic agent of claim 101, wherein the amino acid at position two from the amino terminal amino acid of the epitope is T and the C-terminal amino acid is K.

Claim 103 (New): The diagnostic agent of claim 102, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 104 (New): The diagnostic agent of claim 85, wherein the amino acid at position two from the amino terminal amino acid of the epitope is selected from the group consisting of L, M, V, and T and the C-terminal amino acid is K.

Claim 105 (New): The diagnostic agent of claim 104, wherein the amino acid at position two from the amino terminal amino acid of the epitope is T and the C-terminal amino acid is K.

Claim 106 (New): The diagnostic agent of claim 105, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 107 (New): The diagnostic agent of claim 86, wherein the amino acid at position two from the amino terminal amino acid of the epitope is selected from the group consisting of L, M, V, and T and the C-terminal amino acid is K.

Claim 108 (New): The diagnostic agent of claim 107, wherein the amino acid at position two from the amino terminal amino acid of the epitope is T and the C-terminal amino acid is K.

Claim 109 (New): The diagnostic agent of claim 108, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).